期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

β-受体阻滞剂治疗慢性充血性心力衰竭的研究进展 被引量：2

下载PDF
导出
摘要 本文对充血性心力衰竭 (CHF)患者应用 β-受体阻滞剂治疗的根据。
作者 陈曼华
机构地区 武汉市中心医院心内科
出处 《心脏杂志》 CAS 2002年第5期427-428,432,共3页 Chinese Heart Journal
关键词 β—受体阻滞剂 慢性心力衰蝎 治疗
分类号 R541.605 [医药卫生—心血管疾病]
  • 相关文献

参考文献10

  • 1Steering Committee and membershipof the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensusrecommendation for the management of chronic heart failure[J]. Am JCardiol,1999,83:2A-38A.
  • 2Schrier R,Abraham W. Hormones and hemodynamics in heart failure[J]. N Engl JMed,1999,341:577-585.
  • 3Packer M,Bristow M,Cohn J,et al. The effect of carvedilol on morbidity andmortality in patients with chronic heart faulure[J]. N Engl J Med,1996,334:1349-1355.
  • 4MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heartfailure:Metoprolol CR/XL Randomized Intervention Trial in Congestive HeartFailure(MERIT-HF)[J]. Lancet,1999,353:2001-2007.
  • 5Hjalmarson A,Goldstein S,Fagerberg B,et al. Effects of controlled-releasemetoprolol on total mortality,hospitalizations,and well-being in patients with heartfailure:the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure(MERIT-HF)[J]. JAMA,2000,283:1295-1302.
  • 6CIBIS-Ⅱ investigators and committees. The Cardiac Insufficiency Bisoprolol StudyⅡ(CIBIS-Ⅱ):a randomized trial[J]. Lancet,1999,353:9-13.
  • 7Cardinale V,Chi J. Drug Topics red book[M]. Montvale,NJ:Medical Economics,1999.
  • 8Bleske BE,Glibert EM,Munger MA. Carvedilol:therapeutic application and practiceguidelines[J]. Pharmacotherapy,1998,18:729-737.
  • 9洪中立.慢性心力衰竭治疗和评估的新进展[J].心脏杂志,2001,13(5):406-408. 被引量：2
  • 10Bonet S,Agusti A,Arnau JM,et al. Beta-adrenergic blocking agents in heartfailure:benefits of vasodilating and non-vasodilating agents according to patients′characteristics:a meta-analysis of clinical trails[J]. Arch Intern Med,2000,160:621-627.

二级参考文献16

  • 1[1]CIBIS-Ⅱ Investigators and committees the. cardiac insufficiency bisoprolol study Ⅱ(CIBIS-Ⅱ):a randomized trial[J]. Lancet,1999,353:9-13.
  • 2[2]MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL randomized intervention trial in congestive heart failure(MERIT-HF)[J]. Lancet,1999,353:2001.
  • 3[3]Krum H,Whorlow S. Meta-Analysis of effect of beta-blocker therapy on mortality on NYHA class Ⅳ CHF patients[J]. Circulation(Sepplement 1),1999,100(18):I-208.
  • 4[4]Packer M. COPERNICUS(Carvedilol prospective randomiged cumulative survival):Evaluates the effects of carvedilol top-of ACE on major cardiac events in patients with heart failure NYHAⅡ～ⅣⅩⅩⅡ congress of the europeau society of cardillgy[C], 2000. Aug26～30. Hot-line symposium.
  • 5[5]Zannad F,Perez A,Pitt B,et al. Mechanisms contributing to the survival benefit with aldosterone antagonist therapy in heart failure. Effects on neurohormones and cardiac fibrosis:a substudy of RALES[J]. Eur Heart J,2000,21(Abstract Supplement):22.
  • 6[6]Guazzi M,Pontone G,Agostonip P,et al. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure[J]. Am J Cardiol,1999,84(9):1038-1043.
  • 7[7]Milfred-LaForest SK,Shubert J,Mendoza B,et al. Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and oral angiotensin-converting enzyme inhibitors[J]. Am J Cardiol,1999,84:894-899.
  • 8[8]O'Connor CM,Gattis WA,Uretshy BF,et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure:Insights from the flolan international randomized survival trial(FIRST)[J]. Am Heart J,1999,138(1):78-85.
  • 9[9]Kukin ML,Frendenberger RS,Mannino MM,et al. Short-term and long-term hemnondynamic and clinical effects of metroprolol alone and combined with amlodipine in patients with chronic heart failure[J]. Am Heart J, 1999,138,261-268.
  • 10[10]Consin J,Diez J,Effects of type of diuretic on mortality in patients with chronic congestive heart failure. European Heart J,2000,21(Abstract Supplement):296.

共引文献1

同被引文献20

  • 1张凤如,沈卫峰.心力衰竭的进展(11)β受体阻滞剂治疗心力衰竭及其机制的新认识(续6)[J].中国循环杂志,2006,21(5):323-325. 被引量：3
  • 2陈灏珠,主编.实用内科学[M]第12版.北京:人民卫生出版社,2005.1 231-1 245.
  • 3Liggett SB,Mialet-Perez J,Thaneemit-Chen S,et al.A polymorphism within a conserwed beta adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.Proc Natl Acad Sci USA,2006,103:11288-11293.
  • 4Shin J,Johnson JA.Pharmacogenetics of beta-blockers.Pharmacotherapy,2007,27:874-877.
  • 5SQUIRE IB,Barnett DB.The rational use of β-adreno captor blocker in the treatmentof heart failure.The changing face of an old therapy.Br J Clin Phannacol,2000,49:1-9.
  • 6Katz AM.Regression of left wentricular hypertrophy:new hope for dying hearts.Circulation,1998:623-624.
  • 7Till DG,Rockman HA.Role of beta-adrenergic receptor signaling and desensitization in heart failure:new concepts and prospects for treatment.Expert Rev Cardiovasc Ther,2006,4:147-432.
  • 8Francis GS.Pathophysiology of chronic heart failure.Am J Med,2001,110 Suppl 7A:37-46.
  • 9Braunwald E.Expanding indications for β-blockers in heart failure,N Engl J Med,2001,344:1711-1712.
  • 10Adams Jr KF.Whichβ-blockers for heart failure Editorial.Am Heart J,2001,141:884-888.

引证文献2

二级引证文献13

心脏杂志
2002年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部